Cacciatore L, Cozzolino G, Giardina M G, De Marco F, Sacca L, Esposito P, Francica G, Lonardo A, Matarazzo M, Varriale A
Institute of Internal Medicine, University of Naples, 2nd School of Medicine, Italy.
Diabetes Res. 1988 Apr;7(4):185-8.
The prevalence of impaired glucose tolerance (IGT) and diabetes mellitus (DM) such as defined by National Diabetes Data Group criteria, and glycosylated hemoglobin levels were assessed in a series of consecutive patients who had chronic active hepatitis (CAH) or cirrhosis in the absence of any known diabetogenic risk factors and who had normal fasting glycemic levels. Based on oral glucose tolerance test, the prevalence of IGT (15%) and DM (27%) in cirrhosis was significantly higher (p less than 0.005) than that observed in CAH (0%) and controls (0%). In contrast, HbA1 levels were not statistically different in cirrhotic patients (with normal or altered glucose tolerance) as compared with CAH and control subjects.
(a) HbA1 is an unsatisfactory test in the diagnosis of altered glucose tolerance in patients with cirrhosis, and (b) Cirrhosis (but not CAH) represents itself a risk factor for the development of glucose metabolism alterations. Therefore, routine oral glucose tolerance testing is warranted in these patients.
在一系列无任何已知致糖尿病风险因素且空腹血糖水平正常的慢性活动性肝炎(CAH)或肝硬化连续患者中,评估了根据美国国家糖尿病数据组标准定义的糖耐量受损(IGT)和糖尿病(DM)的患病率以及糖化血红蛋白水平。基于口服葡萄糖耐量试验,肝硬化患者中IGT(15%)和DM(27%)的患病率显著高于CAH患者(0%)和对照组(0%)(p<0.005)。相比之下,肝硬化患者(糖耐量正常或异常)的HbA1水平与CAH患者和对照组相比无统计学差异。
(a)HbA1在诊断肝硬化患者糖耐量改变方面是一项不令人满意的检测;(b)肝硬化(而非CAH)本身是葡萄糖代谢改变发生的一个风险因素。因此,这些患者有必要进行常规口服葡萄糖耐量试验。